Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024

Article

Author: Cremer, Jeroen ; Hoeve, Christina E ; van der Veer, Bas ; Huiberts, Anne J ; Eggink, Dirk ; van den Hof, Susan ; Knol, Mirjam J ; de Melker, Hester E ; van de Wijgert, Janneke HHM ; de Gier, Brechje

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).

15 Feb 2024·Eurosurveillance

2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)

Article

Author: Hasso, Maan ; Zhan, Yuping ; Zelyas, Nathan ; Gao, Ruimin ; Sabaiduc, Suzana ; Mather, Richard G ; Khalid, Ayisha ; Carazo, Sara ; Jassem, Agatha N ; Kaweski, Samantha E ; Skowronski, Danuta M ; Olsha, Romy ; Dickinson, James A ; Charest, Hugues ; Bastien, Nathalie ; Levade, Inès

The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).

01 Jan 2024·Journal of Medical Virology

Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5‐ and BA.5‐XBB‐convalescent subpopulations

Article

Author: Li, Guichang ; Xu, Hao ; Liang, Ziteng ; Chen, Daxiang ; Liu, Siyi ; Zhong, Nanshan ; Cui, Tingting ; Wang, Zhongfang ; Yang, Xiaoyun ; Wang, Yuan ; Huang, Weijin

AbstractThe EG.5.1 variant of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) has been prevalent since mid‐July 2023 in the United States and China. The variant BA.2.86 has become a major concern because it is 34 mutations away from the parental variant BA.2 and >30 mutations from XBB.1.5. There is an urgent need to evaluate whether the immunity of the population and current vaccines are protective against EG.5.1 and BA.2.86. Based on a cohort of two breakthrough‐infected groups, the levels of neutralizing antibodies (NAbs) against different subvariants were measured using pseudovirus‐based neutralization assays. XBB.1.5, EG.5.1, and BA.2.86 are comparably immune‐evasive from neutralization by the plasma of individuals recovered from BA.5 infection (BA.5‐convalescent) or XBB.1.9.2/XBB.1.5 infection following BA.5 infection (BA.5‐XBB‐convalescent). NAb levels against EG.5.1 and BA.2.86 subvariants remained >120 geometric mean titers (GMTs) in BA.5‐XBB‐convalescent individuals 2 months postinfection but were <40 GMTs in BA.5‐convalescent individuals. Furthermore, the XBB‐targeting messenger RNA (mRNA) vaccine RQ3033 induced higher levels of NAbs against XBB.1.5, EG.5.1, and BA.2.86 than against BA.5‐XBB infection. The results suggest that BA.2.86 and EG.5.1 are unlikely to cause more severe concerns than the currently circulating XBB subvariants and that the XBB.1.5‐targeting mRNA vaccine tested has promising protection against EG.5.1 and BA.2.86.

100 Deals associated with RSV mRNA vaccine(RNACure Biopharma)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Syncytial Virus Infections	Phase 2	CN	Walvax Biotechnology Co., Ltd.	-
Respiratory Syncytial Virus Infections	Preclinical	CN	Shanghai Lanque Biomedical Co., Ltd	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

RSV mRNA vaccine(RNACure Biopharma)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation